Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Study of Pemafibrate in Statin-Intolerant Hypercholesterolemia
jRCT2051230055Phase 3Completed
- Sponsor
- Kowa Company, Ltd.
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pemafibrate in hypercholesterolemia (3 arms), sponsored by Kowa Company, Ltd. Primary endpoints: Percent change from baseline in LDL-C at week 4, Percent change from baseline in LDL-C at week 8 and 1 more. Started Jul 2023; status: completed.
02
Drugs
pemafibrate
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on jRCT2051230055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051230055.